
initiating therapy with controlled – release (extended-release) niacin.	■ Please send me The HATS Trial reprint entitled "Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease" from the New England Journal of Medicine.	sist Name	sy Address	State	umber
initiating release)	Please Simvas combina from the	Pharmacist Name	Pharmacy Address	City	Phone Number

Slo-Niacin® – the niacin used in HATS¹

Slo-Niacin® + Simvastatin: lipid changes from baseline



Average daily dose: niacin* 2400 mg \pm 2000 mg; simvastatin 13.6 mg \pm 6 mg.

The HATS trial (HDL-Atherosclerosis Treatment Study) enrolled 160 men (younger than 63 years of age) and women (younger than 70 years of age) with clinical coronary disease (defined as previous myocardial infarction, coronary interventions, or confirmed angina) and with at least three stenosis of at least 30% of the luminal diameter or one stenosis of at least 50%. Twenty-six patients in Canada and 134 patients in the Seattle area were enrolled between January 1995 and January 1997. All patients had low levels of HDL cholesterol (<35 mg/dL for men and <40 mg/dL for women), LDL cholesterol levels of 145 mg/dL or less, and triglyceride levels of 400 mg/dL or less.

'All niacin (both SLO-NIACIN- and Niacor-) supplied and manufactured by Upsher-Smith Laboratories, Inc.

Upsher-Smith Laboratories, Inc. 6701 Evenstad Drive Maple Grove, MN 55369





YOU CAN

Recommend Slo-Niacin® Tablets Newly located in your Vitamin Section!



- ▶ Polygel® controlled-release system delivers gradual, measured doses over time, minimizing side effects
- ▶ Promoted and sampled to physicians
- ► Scored for easy titration

For other information, see package insert or visit: www.upsher-smith.com

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

YOU SHOULD

Recommend Slo-Niacin® Tablets

Slo-Niacin® was the extended-release niacin used in the HATS trial (HDL-Atherosclerosis Treatment Study) with simvastatin.1

- **Reduced** the risk of a cardiovascular event by 90% compared to placebo
- ► <u>Halted</u> the progression of stenosis

Brown BG, et al. Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary Disease, N Engl J Med, Vol 345, No. 22





UPSHER-SMITH LABOF 6701 EVENSTAD DRIVE MAPLE GROVE MN 553

*http://www.drugstore.com/pharmacy/prices/drugprice.asp#60598000101_prices.